20/20 Biolabs Inc (NASDAQ:AIDX – Get Free Report) was the recipient of a large drop in short interest during the month of October. As of October 15th, there was short interest totaling 11,270 shares, a drop of 75.0% from the September 30th total of 45,167 shares. Currently, 0.1% of the shares of the stock are sold short. Based on an average trading volume of 131,753 shares, the days-to-cover ratio is currently 0.1 days.
20/20 Biolabs Stock Performance
AIDX traded down $0.02 during trading on Thursday, reaching $0.23. The stock had a trading volume of 103,239 shares, compared to its average volume of 401,224. The stock has a market cap of $3.06 million and a PE ratio of -0.42. 20/20 Biolabs has a one year low of $0.23 and a one year high of $50.00. The business has a 50-day moving average of $0.44 and a 200-day moving average of $1.00.
20/20 Biolabs (NASDAQ:AIDX – Get Free Report) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.26) earnings per share for the quarter. The business had revenue of $0.73 million during the quarter.
Wall Street Analyst Weigh In
Separately, Weiss Ratings upgraded shares of 20/20 Biolabs from a “sell (e-)” rating to a “sell (e)” rating in a research report on Monday, August 3rd. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, 20/20 Biolabs has an average rating of “Hold” and a consensus price target of $5.00.
Get Our Latest Stock Report on 20/20 Biolabs
20/20 Biolabs Company Profile
We develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. We offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, blood test which has been our primary commercial focus and source of revenues since we wound down our COVID-19 testing business, and (ii) OneTest for Longevity, which measures inflammatory biomarkers, that we expect to launch in the first half of 2026.
See Also
- Five stocks we like better than 20/20 Biolabs
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
Receive News & Ratings for 20/20 Biolabs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 20/20 Biolabs and related companies with MarketBeat.com's FREE daily email newsletter.
